Sort
10,766 grants matching “checkpoint inhibitor”
An Engineered CRISPR System for Boosting Tumor Immunogenicity.
$246,000Weixin Tang · University Of Chicago · R21 · FY2021 · EB
Administrative Core
$245,640Peter Karl Sorger · Harvard Medical School · U54 · FY2022 · CA
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis
$245,639David R Spriggs · Sloan-Kettering Inst Can Research · U01 · FY2012 · CA
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
$245,617Yong Wan · Northwestern University At Chicago · R01 · FY2019 · CA
Project 2: Microenvironment Modification and Anti-PD1 Immunotherapy of Lymphoma
$245,601George J Weiner · University Of Iowa · P50 · FY2021 · CA
Targeting the stress-specific function of replication protein A in oral squamous cell carcinoma
$245,504Aimin Peng · Univ Of North Carolina Chapel Hill · R21 · FY2025 · DE
TRAIL-induced Cell Death in Breast Cancer Cells
$245,431Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2013 · CA
Biochemical Basis for Therapeutic Activity
$245,138William K Plunkett · University Of Tx Md Anderson Can Ctr · R01 · FY2006 · CA
Role of Acid in the Development of Barrett's Esophagus
$245,114Rhonda F Souza · Ut Southwestern Medical Center · R01 · FY2010 · DK
Project 2: Intratumoral PDT Induces PDP-based Enhancement of PD-1 Inhibition in Pancreatic Carcinoma
$245,034Vinay Chandrasekhara · Massachusetts General Hospital · P01 · FY2023 · CA
CDK inhibitor regulation during the Xenopus cell cycle
$245,004P. Renee Yew · University Of Texas Hlth Science Center · R01 · FY2006 · GM
Targeted Therapy for Endometrial Cancer
$244,874Kimberly K Leslie · University Of Iowa · R01 · FY2014 · CA
Mechanisms of ATR Targeting and Regulation
$244,833Randal Scot Tibbetts · University Of Wisconsin-Madison · R01 · FY2007 · GM
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR
$244,801Sean S Park · Mayo Clinic Rochester · R01 · FY2018 · CA
Vitamin D and Ovarian Cancer Prevention and Treatment
$244,382Wenlong Bai · University Of South Florida · R01 · FY2008 · CA
SPORE: Targeted Therapies for Glioma
$244,260Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2021 · CA
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
$244,207Binfeng Lu · Hackensack University Medical Center · R01 · FY2022 · CA
Targeting the Stroma for Pancreatic Cancer Treatment
$244,172Arsen Osipov · Cedars-Sinai Medical Center · K08 · FY2024 · CA
Targeting the Stroma for Pancreatic Cancer Treatment
$244,172Arsen Osipov · Cedars-Sinai Medical Center · K08 · FY2025 · CA
Targeting the Stroma for Pancreatic Cancer Treatment
$244,172Arsen Osipov · Cedars-Sinai Medical Center · K08 · FY2021 · CA
Targeting the Stroma for Pancreatic Cancer Treatment
$244,172Arsen Osipov · Cedars-Sinai Medical Center · K08 · FY2023 · CA
Targeting the Stroma for Pancreatic Cancer Treatment
$244,172Arsen Osipov · Cedars-Sinai Medical Center · K08 · FY2022 · CA
Regulation of DNA replication fork progression by ATM kinase activity
$243,945Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2014 · CA
Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer
$243,938Kent W Mouw · Dana-Farber Cancer Inst · R21 · FY2022 · CA
Development of a novel checkpoint inhibitor-TGF beta combination therapy to reverse immune suppression and increase survival rates in advanced colorectal cancer patients
$243,905Dori A Thomas-Karyat · Synthis Therapeutics, Inc. · R43 · FY2019 · CA